PT -期刊文章盟罗科,帕特里夏·m . AU -席尔瓦,佩德罗·l . AU -克鲁兹,费尔南达f . AU - Melo-Junior,马可·安东尼奥·c . AU - Tierno保罗F.G.M.M. AU -莫拉,马科斯a . AU - De Oliveira Luis Frederico g . AU -利马c c . AU -多斯桑托斯,伊齐答:非盟-初级,沃尔特·f . AU -费尔南德斯,安娜葆拉·克里盟——FranchiniKleber g . AU - Magri埃里克AU -德·莫拉埃斯,奈良f . AU - Goncalves,何塞马里奥•j . AU - Carbonieri梅勒妮n . AU -多斯桑托斯Ivonise s . AU - Paes纳塔莉亚f . AU -马舍尔,宝拉V.M.盟——罗查Raissa p . AU -卡瓦略·亚历克斯·f . AU -阿尔维斯、佩德罗·奥古斯托。非盟- Proenca-Modena Jose Luiz盟——Cordeiro,阿图尔t . AU - Trivella,Daniela b.b.au - Marques, Rafael e . AU - Luiz, Ronir R. AU - Pelosi, Paolo AU - Lapa e Silva, Jose Roberto ED -， TI -早期应用硝唑尼特治疗轻症COVID-19:随机、安慰剂对照试验援助- 10.1183/13993003.03725 -2020 DP - 2021年7月01 TA -欧洲呼吸杂志》第六PG - 2003725 - 58 IP - 1 4099 - //www.qdcxjkg.com/content/58/1/2003725.short 4100 - //www.qdcxjkg.com/content/58/1/2003725.full所以欧元和J2021 7月01;背景硝唑尼特在体外广泛应用并具有广谱抗病毒活性。然而，没有证据表明其对严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)感染的影响。方法在一项多中心、随机、双盲、安慰剂对照试验中，纳入在2019冠状病毒病(COVID-19)发病后3天内出现症状(干咳、发烧和/或疲劳)的成年患者。在鼻咽拭子上使用逆转录酶PCR确认SARS-CoV-2感染后，患者按1:1随机接受硝唑尼特(500 mg)或安慰剂，每日3次，持续5天。主要结果是症状完全缓解。次要结果是病毒载量、实验室检测、炎症的血清生物标志物和住院率。 Adverse events were also assessed.Results From June 8 to August 20, 2020, 1575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analysed. Median (interquartile range) time from symptom onset to first dose of study drug was 5 (4–5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm versus 18.2% in the placebo arm (p=0.009). Viral load was reduced after nitazoxanide compared to placebo (p=0.006). The percentage viral load reduction from onset to end of therapy was higher with nitazoxanide (55%) than placebo (45%) (p=0.013). Other secondary outcomes were not significantly different. No serious adverse events were observed.Conclusions In patients with mild COVID-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.This was the first study to evaluate the effect of early nitazoxanide therapy in mild COVID-19. Nitazoxanide did not accelerate symptom resolution after 5 days of therapy, but did reduce viral load significantly with no serious adverse events. https://bit.ly/37i75pr